Manufacturer of Controlled Substances; Notice of Application; Noramco, Inc. (GA), 37241-37242 [2013-14458]

Download as PDF 37241 Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices Basic class Meperidine Intermediate—A ................................................................................................................................. Meperidine Intermediate—B ................................................................................................................................. Meperidine Intermediate—C ................................................................................................................................. Metazocine ............................................................................................................................................................ Methadone (for sale) ............................................................................................................................................ Methadone Intermediate ....................................................................................................................................... Methamphetamine ................................................................................................................................................ 6 11 6 6 25,000,000 32,500,000 3,912,500 Proposed or proposed adjusted 2013 quotas Previously established 2013 quotas g g g g g g g No change. No change. No change. No change. 33,125,000 g. 40,500,000 g. No change. [987,500 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,863,750 grams for methamphetamine mostly for conversion to a schedule III product; and 61,250 grams for methamphetamine (for sale)] Methylphenidate .................................................................................................................................................... Morphine (for conversion) ..................................................................................................................................... Morphine (for sale) ............................................................................................................................................... Nabilone ................................................................................................................................................................ Noroxymorphone (for conversion) ........................................................................................................................ Noroxymorphone (for sale) ................................................................................................................................... Opium (powder) .................................................................................................................................................... Opium (tincture) .................................................................................................................................................... Oripavine ............................................................................................................................................................... Oxycodone (for conversion) ................................................................................................................................. Oxycodone (for sale) ............................................................................................................................................ Oxymorphone (for conversion) ............................................................................................................................. Oxymorphone (for sale) ........................................................................................................................................ Pentobarbital ......................................................................................................................................................... Phenazocine ......................................................................................................................................................... Phencyclidine ........................................................................................................................................................ Phenmetrazine ...................................................................................................................................................... Phenylacetone ...................................................................................................................................................... Racemethorphan .................................................................................................................................................. Remifentanil .......................................................................................................................................................... Secobarbital .......................................................................................................................................................... Sufentanil .............................................................................................................................................................. Tapentadol ............................................................................................................................................................ Thebaine ............................................................................................................................................................... 80,750,000 103,750,000 60,250,000 25,628 9,000,000 508,750 91,250 1,287,500 22,750,000 10,250,000 131,500,000 18,375,000 6,875,000 42,500,000 6 30 3 20,000,000 3 3,750 215,003 6,255 13,750,000 145,000,000 g g g g g g g g g g g g g g g g g g g g g g g g 96,750,000 g. 91,250,000 g. No change. No change. No change. 1,262,500 g. No change. No change. No change. No change. 153,750,000 g. No change. No change. No change. No change. No change. No change. 29,628,750 g. No change. No change. No change. No change. No change. No change. 15,100,000 3,500,000 25,700,000 6,100,000 225,000,000 g g g g g No No No No No List I Chemicals Ephedrine (for conversion) ................................................................................................................................... Ephedrine (for sale) .............................................................................................................................................. Phenylpropanolamine (for conversion) ................................................................................................................. Phenylpropanolamine (for sale) ............................................................................................................................ Pseudoephedrine (for sale) .................................................................................................................................. The Deputy Administrator further proposes that aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Pursuant to 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Deputy Administrator may adjust the 2013 aggregate production quotas and assessment of annual needs as needed. TKELLEY on DSK3SPTVN1PROD with NOTICES Comments Pursuant to 21 CFR 1303.11 and 21 CFR 1315.11, any interested person may submit written comments on or objections to these proposed determinations. Based on comments received in response to this Notice, the Deputy Administrator may hold a public hearing on one or more issues raised. In the event the Deputy Administrator decides in his sole VerDate Mar<15>2010 17:01 Jun 19, 2013 Jkt 229001 discretion to hold such a hearing, the Deputy Administrator will publish a notice of any such hearing in the Federal Register. After consideration of any comments and after a hearing, if one is held, the Deputy Administrator will publish in the Federal Register a Final Order establishing any adjustment of 2013 aggregate production quota for each basic class of controlled substance and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. Dated: June 14, 2013. Thomas M. Harrigan, Deputy Administrator. [FR Doc. 2013–14723 Filed 6–19–13; 8:45 am] BILLING CODE 4410–09–P PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 change. change. change. change. change. DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Noramco, Inc. (GA) Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 21, 2012, Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Opium tincture (9630), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substance in bulk for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, E:\FR\FM\20JNN1.SGM 20JNN1 37242 Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than August 19, 2013. Dated: June 7, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Office of Justice Programs [OJP (NIJ) Docket No. 1624] Draft Report and Recommendations Prepared by the Research Committee of the Scientific Working Group on Medicolegal Death Investigation National Institute of Justice, DOJ. Notice and request for comments. ACTION: In an effort to obtain comments from interested parties, the U.S. Department of Justice, Office of Justice Programs, National Institute of Justice, Scientific Working Group for Medicolegal Death Investigation will make available to the general public a document entitled, ‘‘Research in Forensic Pathology/Medicolegal Death Investigation’’. The opportunity to provide comments on this document is open to coroner/medical examiner office representatives, law enforcement agencies, organizations, and all other stakeholders and interested parties. Those individuals wishing to obtain and provide comments on the draft document under consideration are directed to the following Web site: http://www.swgmdi.org. DATES: Comments must be received on or before July 29, 2013. FOR FURTHER INFORMATION CONTACT: Patricia Kashtan, by telephone at 202– 353–1856 [Note: this is not a toll-free telephone number], or by email at Patricia.Kashtan@usdoj.gov. TKELLEY on DSK3SPTVN1PROD with NOTICES SUMMARY: Greg Ridgeway, Acting Director, National Institute of Justice. [FR Doc. 2013–14707 Filed 6–19–13; 8:45 am] BILLING CODE 4410–18–P VerDate Mar<15>2010 17:01 Jun 19, 2013 Jkt 229001 Request for Public Comments: Interagency Review of Exclusion Order Enforcement Process Office of the U.S. Intellectual Property Enforcement Coordinator, Executive Office of the President, OMB. ACTION: Request for written submissions from the public. AGENCY: The Executive Office of the President, through the U.S. Intellectual Property Enforcement Coordinator (‘‘IPEC’’), is beginning an interagency review directed at strengthening the procedures and practices used during enforcement of exclusion orders issued by the U.S. International Trade Commission (‘‘ITC’’). The interagency working group will review existing procedures that U.S. Customs and Border Protection (‘‘CBP’’) and the ITC use to evaluate the scope of exclusion orders and work to ensure the process and criteria utilized during exclusion order enforcement activities are transparent, effective, and efficient. Through this request for public comment, IPEC invites public input and recommendations in support of the Administration’s interagency review of exclusion order enforcement processes called for by the 2013 Joint Strategic Plan on Intellectual Property Enforcement [and the White House Task Force on High-Tech Patents]. DATES: Submissions must be received on or before July 21, 2013, at 11:59 p.m. ADDRESSES: All submissions should be electronically submitted to http:// www.regulations.gov. If you are unable to provide submissions to regulations.gov, you may contact the Office of the U.S. Intellectual Property Enforcement Coordinator at intellectualproperty@omb.eop.gov using the subject line ‘‘IPEC Review of Exclusion Order Enforcement Processes’’ or (202) 395–1808 to arrange for an alternate method of transmission. The regulations.gov Web site is a Federal E-Government Web site that allows the public to find, review and submit comments on documents that have published in the Federal Register and that are open for comment. Submissions filed via the regulations.gov Web site will be available to the public for review and inspection. For this reason, please do not include in your comments information of a confidential nature, such as sensitive personal information or proprietary business information. FOR FURTHER INFORMATION CONTACT: Office of the U.S. Intellectual Property SUMMARY: [FR Doc. 2013–14458 Filed 6–19–13; 8:45 am] AGENCY: OFFICE OF MANAGEMENT AND BUDGET PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 Enforcement Coordinator, at intellectualproperty@omb.eop.gov or (202) 395–1808. SUPPLEMENTARY INFORMATION: Under Section 337 of the Tariff Act of 1930, the ITC investigates allegations regarding unfair practices in import trade, including allegations related to intellectual property infringement, as well as other forms of unfair competition. Once the ITC finds a violation of Section 337 and issues an exclusion order barring the importation of infringing goods, CBP and the ITC are responsible for determining whether imported articles fall within the scope of the exclusion order. Because of these shared responsibilities, it is critical that the ITC and CBP have clear communication on what the order means to improve the order’s enforcement and prevent importation of infringing product. This determination can often be challenging, particularly in cases in which a technologically sophisticated product may have been redesigned so as to no longer fall within the scope of the existing exclusion order. IPEC will chair a new interagency effort directed at strengthening the processes that CBP uses with regard to enforcement of ITC exclusion orders pertaining to intellectual property. The working group will be comprised of representatives from the ITC; DHS, DOC, Treasury, and DOJ; offices within the Executive Office of the President including USTR, OSTP, NEC; and other relevant agencies as necessary. The interagency working group will review existing procedures that CBP and the ITC use to evaluate the scope of ITC exclusion orders and work to ensure the process and standards utilized during exclusion order enforcement activities are transparent, effective, and efficient. Among others, one focus of the interagency review will be on ensuring that CBP uses transparent and accurate procedures for determining whether an article is covered by the ITC exclusion order. Further, the working group will evaluate opportunities to improve the effectiveness of directions provided by the ITC to assist CBP with the challenges of enforcement. Important to the development of the Administration’s exclusion order enforcement recommendations, is ensuring that any approaches that are considered to be particularly effective as well as any concerns with the present approach to exclusion order enforcement are understood by policymakers. As such, IPEC is seeking public input and recommendations through the questions set out below for E:\FR\FM\20JNN1.SGM 20JNN1

Agencies

[Federal Register Volume 78, Number 119 (Thursday, June 20, 2013)]
[Notices]
[Pages 37241-37242]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14458]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; 
Noramco, Inc. (GA)

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 21, 2012, Noramco, 
Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Opium tincture (9630), a basic class of controlled 
substance listed in schedule II.
    The company plans to manufacture the listed controlled substance in 
bulk for distribution to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substance,

[[Page 37242]]

may file comments or objections to the issuance of the proposed 
registration pursuant to 21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administrator, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than August 19, 2013.

     Dated: June 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-14458 Filed 6-19-13; 8:45 am]
BILLING CODE 4410-09-P